Neoadjuvant ipilimumab-nivolumab superior to adjuvant nivolumab

被引：0
|
作者：
Sidaway, Peter
机构：
[1] Nature Reviews Clinical Oncology,
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2024年 / 21卷 / 08期
关键词：
D O I：
10.1038/s41571-024-00916-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：566 / 566
页数：1
相关论文
共 50 条
  • [31] Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma
    Su, Y.
    Lin, Y.
    Hsiao, C.
    Ou, D.
    Chen, S.
    Wu, Y.
    Lee, W.
    Lin, J.
    Hsu, C.
    Ho, M.
    Lu, L.
    Wu, T.
    Lai, S.
    Chao, Y.
    Chou, T.
    Yen, C.
    Chen, L.
    Shan, Y.
    Cheng, A.
    Hsu, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S141 - S141
  • [32] Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
    Weber, J.
    Mandala, M.
    Del Vecchio, M.
    Gogas, H. J.
    Arance, A. M.
    Cowey, C. L.
    Dalle, S.
    Schenker, M.
    Chiarion-Sileni, V.
    Marquez-Rodas, I.
    Grob, J-J.
    Butler, M. O.
    Middleton, M. R.
    Maio, M.
    Atkinson, V.
    Queirolo, P.
    Gonzalez, R.
    Kudchadkar, R. R.
    Smylie, M.
    Meyer, N.
    Mortier, L.
    Atkins, M. B.
    Long, G. V.
    Bhatia, S.
    Lebbe, C.
    Rutkowski, P.
    Yokota, K.
    Yamazaki, N.
    Kim, T. M.
    de Pril, V.
    Sabater, J.
    Qureshi, A.
    Larkin, J.
    Ascierto, P. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19): : 1824 - 1835
  • [33] Cabozantinib + nivolumab and ipilimumab/nivolumab have differing safety profiles
    Reactions Weekly, 2023, 1979 (1) : 6 - 6
  • [34] Ipilimumab/nivolumab/nivolumab/pembrolizumabType 1 diabetes: case report
    Reactions Weekly, 2023, 1956 (1) : 286 - 286
  • [35] A case of thoracic SMARCA4-Deficient undifferentiated tumor successfully treated with combination Ipilimumab-Nivolumab
    Nakano, Yoshio
    Sekinada, Daisuke
    Kuze, Yusuke
    Okamoto, Norio
    Gohma, Iwao
    Yasuhara, Yumiko
    CLINICAL CASE REPORTS, 2022, 10 (12):
  • [36] Ipilimumab and Nivolumab Induced Gastritis
    Jaiswal, Palashkumar
    Yap, John Erikson
    Attar, Bashar M.
    Mishra, Satya
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S1444 - S1445
  • [37] Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)
    Cascone, T.
    William, W. N.
    Weissferdt, A.
    Leung, C. H.
    Federico, L.
    Haymaker, C.
    Bernatchez, C.
    Fossella, F. V.
    Mott, F. E.
    Papadimitrakopoulou, V. A.
    Byers, L.
    Lam, V. K.
    Godoy, M. C.
    Carter, B.
    Lee, J. J.
    Vaporciyan, A.
    Gibbons, D. L.
    Swisher, S. G.
    Heymach, J. V.
    Sepesi, B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [38] Neoadjuvant nivolumab/relatlimab or nivolumab/ ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs)
    Nederlof, I.
    Rolfes, A. L.
    Gielen, R. C. A. M.
    Awada, G.
    Dongen, M. V.
    Horlings, H. M.
    Van De Vijver, K.
    Drukker, C. A.
    Van Duijnhoven, F.
    Lopez-Yurda, M.
    Mandjes, I.
    Mann, R. M.
    Loo, C. E.
    Blank, C. U.
    Schumacher, T. N.
    Salgado, R. F.
    Kok, M.
    ANNALS OF ONCOLOGY, 2024, 35 : 1206 - 1206
  • [39] Cost effectiveness of combination ipilimumab-nivolumab in advanced non-small-cell lung cancer.
    Courtney, Patrick T.
    Yip, Anthony T.
    Cherry, Daniel R.
    Salans, Mia A.
    Kumar, Abhishek
    Murphy, James Don
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Ipilimumab and nivolumab: fatal myocarditis
    Reactions Weekly, 2016, 1628 (1) : 7 - 7
12345